An observational study in HIV and Insomnia, sponsored by University of Alabama at Birmingham. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by University of Alabama at Birmingham · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States — 149 open to participants now, 186 under way, 5 of them phase 3. Sleep Initiation and Maintenance Disorders · United States.
Among the 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States, this one is the 16th largest by enrollment of the 49 observational ones that give a count, is one of 49 that started in 2020, is one of 49 observational ones, and was the 541st registered.
2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →149 of the 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States are open now. Recruiting first, the newest first:
Olly, PBC · Sites in United States
Ages 4–16 · Healthy volunteers
Indiana University · Sites in United States
Ages 18+ · Healthy volunteers
Spectrum Clinical Research, LLC · Sites in United States
Ages 45–65 · Women only
Florida State University · Sites in United States
Ages 6–13 · Healthy volunteers
University of Pittsburgh · Sites in United States
Ages 65+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
907 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 103 · Phase 3 77 · Phase 4 78
First in 1997; this study’s year is marked. 49 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 171 is above the median of 138 across 321 observational studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 60 across the 858 interventional studies, 68 across the 49 observational. Of the 661 that completed or were terminated, 243 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
187 of 907 have an industry lead sponsor. The 10 most frequent:
University of Alabama at Birmingham is the lead sponsor of 1,422 studies on the registry; 277 are open to participants now.
Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.
University of Alabama at Birmingham has 4 studies filed under Sleep Initiation and Maintenance Disorders — fewer than ten, so there is no comparison to draw.
80 of the studies in Sleep Initiation and Maintenance Disorders with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06568367Phase 3Axsome Therapeutics, Inc.Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN) | 2026-12 |
| NCT06655883Phase 3Merck Sharp & Dohme LLCA Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098) | 2027-06-24 |
| NCT07336277Phase 3Emory UniversitySleep Quality and the Efficacy of a Multimodal Sleep Pathway in Hospitalized Orthopedic Trauma Patients | 2027-07 |
| NCT06953869Phase 3Vanda PharmaceuticalsEvaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia | 2027-11 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
Add all 80 to your calendar (.ics) → With an account.
Among the 907 studies in Sleep Initiation and Maintenance Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overall objective of this application is to investigate the impact of insomnia on pain, physical functioning, and inflammation in people living with HIV. The two aims of this study to determine 1) whether insomnia promotes increased sensitivity and inflammatory reactivity to pain stimuli, and 2) if weekly fluctuations in insomnia burden drive changes in inflammation, pain severity, and physical functioning in people living with HIV. This research could help confirm insomnia as a therapeutic target for the suppression of pain and inflammation in people living with HIV.
This study was conducted during the height of the COVID19 pandemic. Recruitment and retention were significantly and negatively affected. The longitudinal time-course was reduced from 8 consecutive weeks of observation down to 3 weeks. We were only able to recruit 171 of an anticipated 200 participants.
Week 1: 171 total participants Week 2: 136 total participants Week 3: 35 participants (insomnia only)
Week 1 Resting Blood Pressure and Body Mass Index will be assessed. Participants who have an HIV negative status will complete the OraQuick Advance Rapid HIV 1/2 Swab test. Study staff will administer the Structured Interview for Sleep Disorders and administer the Rapid Estimation of Adult Literacy Measure-Short Form (REALM-SF) to determine health literacy. The night of Experimental Session 1 participant will be using a Resmed ApneaLink Air device (Resmed, San Diego, CA), to identify apnea and hypopnea and calculate an apnea hypopnea index.
Between Week 1 and Week 2 Sleep assessment: Sleep data will be collected by participants in their own homes using objective and subjective measures of their sleep. Participant instructions for how to collect and record their own sleep data will be provided at the end of study session 1. Participant will be provided with a watch-like device to wear on wrist for 7 consecutive days and nights. This watch measures physical activity and sleep.
Week 2 Resting Blood Pressure and temperature will be assessed. A sample of urine will be taken to test for illicit substances that might affect the study's results. Experimental session 2 will take place in the Center for Clinical and Translational Science (CCTS) Clinical Research Unit (CRU). A clinical Research Unit (CRU) nurse will place an intravenous (IV) cannula (small plastic tube) in the arm using a needle to draw blood at the beginning of the session and then an additional four times across the study for a total of five blood draws. Participants will complete multiple questionnaires to measure health, and experience with insomnia, pain, mood and emotions, experiences with stigma and discrimination, and how participant thinks and feels about things. All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 3-4 hours. Blood will be processed and stored and then used to measure inflammation.
Week 3 Only participants with insomnia (with and without HIV) will complete a battery of ecologically valid movement tasks that include: 1) Performance Battery (SPPB) which includes sitting in a chair, transitioning to a standing position, balancing tests and gait speed, and the Timed Up and Go test (TUG). A clinical Research Unit (CRU) nurse will draw a quick sample of approximately 20 milliliters from the participants arm using a butterfly needle so that CRU nurse can collect blood during the beginning of each visit.
120 individuals with HIV (60 with insomnia \& 60 without insomnia) as well as a group of 120 individuals without HIV as Controls (60 with insomnia \& 60 without insomnia), for a total sample size of 240 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
with Insomnia
HIV Without Insomnia
Non HIV with Insomnia
Non HIV Without Insomnia
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will test positive for HIV and Insomnia.
Diagnostic Test: Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)sleep disorders-revised · Diagnostic Test: Resmed ApneaLink Air device (Resmed, San Diego, CA). · Other: Quantitative Sensory testing (QST) · Diagnostic Test: Cluster of Differentiation 4 (CD4) and Viral load
Participants will test positive for HIV and test negative for Insomnia.
Diagnostic Test: Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)sleep disorders-revised · Diagnostic Test: Resmed ApneaLink Air device (Resmed, San Diego, CA). · Other: Quantitative Sensory testing (QST) · Diagnostic Test: Cluster of Differentiation 4 (CD4) and Viral load
Participants will test negative for HIV and test positive for Insomnia.
Diagnostic Test: Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)sleep disorders-revised · Diagnostic Test: Resmed ApneaLink Air device (Resmed, San Diego, CA). · Other: Quantitative Sensory testing (QST) · Diagnostic Test: OraQuick Advance Rapid HIV 1/2 Swab test
Participants will test negative for HIV and test negative for Insomnia.
Diagnostic Test: Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)sleep disorders-revised · Diagnostic Test: Resmed ApneaLink Air device (Resmed, San Diego, CA). · Other: Quantitative Sensory testing (QST) · Diagnostic Test: OraQuick Advance Rapid HIV 1/2 Swab test
Structured Clinical Interview For DSM-5 Sleep Disorders-Revised (SCISD-R) - is a semi structured interview for diagnosing sleep disorders according to Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)
Also known as: Structured Clinical Interview For DSM-5 Sleep Disorders-Revised (SCISD-R)
Home Sleep Test (HST) will measure airflow (i.e., nasal pressure) using a nasal cannula and oxygen saturation to identify apnea and hypopnea and calculate an apnea hypopnea index (AHI; number of apnea and hypopnea per hour).
Also known as: Home Sleep Test
All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.
Participants who have an HIV negative status will complete the OraQuick Advance Rapid HIV 1/2 Swab test to confirm negative status.
Also known as: OraQuick
Participants who have an HIV positive status will have blood tested for cluster of differentiation 4 (CD4) and Viral load to confirm positive status.
Pro-Inflammatory Markers
TNF-a, IL-6, IL-12, IL-18, C-reactive protein, sCD14/163, D-dimer and IFN-gamma assays will be performed on the blood to identify levels of pro-inflammatory markers.
Time frame: Week 2; 5 blood draws before, during and after quantitative sensory testing; data is average of these 5 samples
Anti-Inflammatory Markers
IFN-a, TGF-B, IL4, IL-10 and IL-13 assays will be performed on the blood to identify levels of anti-inflammatory markers.
Time frame: Week 2; 5 blood draws before, during and after quantitative sensory testing; data is average of these 5 samples
Oxidative Stress Markers
Mitochondrial DNA damage, Damage associated molecular patterns (DAMPS) and Cortisol assays will be performed on the blood to identify levels of oxidative stress markers.
Time frame: Week 2; 5 blood draws before, during and after quantitative sensory testing; data is average of these 5 samples
Pain Threshold
Pain threshold refers to the intensity at which a stimulus is first perceived as painful. Heat stimuli will be delivered using a computer-controlled thermal stimulation system with a 30 millimeter X 30 millimeter probe. From a baseline of 32 degrees Celsius, the probe temperature will increase at a rate of .5 degrees Celsius/second until the participant responds by pressing a button on a handheld device. For heat pain threshold, participants will be instructed to press the button when the sensation "first becomes painful"
Time frame: pain threshold assessed at Week 2; data is average of three assessments
Pain Tolerance
Pain tolerance refers to the maximum amount of pain produced by a stimulus that a person is able/willing to tolerate. Heat stimuli will again be delivered using the computer-controlled thermal stimulation system. From a baseline of 32 degrees Celsius, the probe temperature will increase at a rate of .5 degrees Celsius/second until the participant responds by pressing a button on a handheld device. For heat pain tolerance, participants will be instructed to press the button when they are "no longer willing to tolerate" the painful sensation.
Time frame: pain tolerance assessed at Week 2; data is average of three assessments
Punctate Stimuli
Mechanical temporal summation was assessed using a nylon Von Frey Filament (Stoelting Co., 6.65 g), which is calibrated to bend at 300 g of pressure. The filament was applied to the back of the non-dominant hand for approximately 1 second until the monofilament bent slightly. Participants were instructed to rate their pain level using the 0-100 Numeric Rating Scale (higher numbers represent greater pain). The filament was then applied to the skin for a series of 10 consecutive applications. Participants were instructed to rate the highest level of pain they experienced during the trial. This process was repeated for two trials (2 single trials, 2 series of 10). For each trial, a difference score was calculated between the series of 10 applications and the single presentation, which represented mechanical TS. The difference score was averaged across the two trials.
Time frame: mechanical temporal summation of pain assessed at Week 2; data is average of two test trials
Temporal Summation of Pain
Temporal summation of pain refers to a form of endogenous pain facilitation characterized by the perception of increased pain despite constant or even reduced peripheral afferent input. Temporal summation is presumed to be the psychophysical manifestation of wind-up. Wind-up is a phenomenon where repetitive stimulation of C primary afferents at rates greater than 0.3 Hertz produces a slowly increasing response of second-order neurons in the spinal cord. A series of 5 heat pulses will be repeated every two seconds starting at a baseline temperature of 40 and participants will be asked to rate how painful each peak of the pulse feels to them using a pain rating of 0-100 numeric rating scale. Pain intensity was assessed using a 0-100 numeric rating scale, where 0 indicates no pain and 100 indicates the worst pain imaginable. Participants rated their pain intensity, with higher scores indicating greater pain severity. Temperatures included 44, 46, and 48 degrees in Celsius.
Time frame: heat temporal summation of pain assessed at Week 2; data presented is the average of 5 heat pulses completed at 44, 46, and 48 degrees in Celsius.
Conditioned Pain Modulation
A cold-water bath (conditioning stimulus) was set to 10°C prior to the visit. Participants placed their non-dominant hand in the water bath up to their wrist for a maximum of 60 seconds. Immediately after withdrawal of the hand from the cold water, pressure was then applied to the dominant forearm or trapezius muscle using an algometer (testing stimulus). Participants were instructed to press a button when they first felt pain, resulting in termination of the stimuli. This procedure was repeated for a total of 4 trials (2 on each body site) and body site order was randomized (i.e., Forearm, Trapezius, Forearm, Trapezius, Forearm). An average pressure pain threshold score (kiloPascals - kPa of pressure) was generated across the two trials at each site after water immersion. Conditioned pain modulation was calculated as the difference score between baseline pressure pain threshold (kPa) and the average pressure pain threshold after water immersion at each body site
Time frame: Week 2
Actigraph Sleep Measurement
A light weight and compact watch-like device used for objective measurement of sleep. The device will be worn for 7 consecutive days/nights and will track physical activity, falling asleep and waking events, and includes an integrated light sensor for recording photopic light.
Time frame: seven consecutive nights of actigraphic sleep monitoring between week 1 and week 2; data reported is average
Weekly Sleep Diaries
A sleep diary including daily questions will be filled out every day for seven days including questions about a participants nightly sleep experiences.
Time frame: Baseline up to 8 weeks
Weekly Caffeine Diaries
A caffeine dairy including different types of caffeine generally available for the participants to record their daily caffeine consumption of for seven days.
Time frame: Baseline up to 8 weeks
Actigraph Sleep Measurement
A light weight and compact watch-like device used for objective measurement of sleep. The device will be worn for 7 consecutive days/nights and will track physical activity, falling asleep and waking events, and includes an integrated light sensor for recording photopic light. The primary actigraphic sleep outcome presented here is sleep efficiency. Sleep efficiency will be assessed using wrist-worn actigraphy and calculated as the percentage of time spent asleep relative to the total time spent in bed during the designated sleep period. Sleep efficiency is derived by dividing total sleep time by time in bed and multiplying by 100. The mean scores presented here are percentages. Higher percentages indicate greater sleep efficiency.
Time frame: seven consecutive nights of actigraphic sleep monitoring between week 1 and week 2; data reported is average
Short Physical Performance Battery
The Short Physical Performance Battery consists of 3 individual sub-tests - standing balance (participants are asked to stand in 3 easy stances for 10 seconds), 4-meter gait speed (participants are asked to walk a steady pace in a straight line for 4-meters) and 5-repetition sit-to-stand (participants are asked to stand up and sit back down in a stable chair up to 5 times). All 3 are simple and quick to perform in the outpatient setting and require only limited equipment. The total short physical performance battery score ranges from 0-12, with higher scores indicating better physical performance.
Time frame: Completed at Week 3 by people with insomnia only
Timed Up and Go (TUG) Task
The Timed Up and Go test (TUG) is a commonly used screening tool to assist clinicians to identify patients at risk of falling. Participants are asked to start in a sitting position in a chair, stand up and walk approximately 3 meters before turning to return to the chair at a steady, straight pace. The outcome will be measured with a stopwatch, then rating difficulty 0-100 (0 no difficulty and 100 being the most difficult imaginable) and pain 0-100 (0 no pain and 100 being the most pain imaginable).
Time frame: Completed at Week 3 by people with insomnia only
Munich Chrono Type Questionnaires (MCTQ)
The Munich Chronotype Questionnaire (MCTQ) estimates chronotype primarily from the midpoint of sleep on free days, called MSF (mid-sleep on free days), with MSFsc (sleep-corrected MSF) generally preferred because it adjusts for accumulated weekday sleep debt. The outcome reported in this trial is expressed in minutes - "mid-sleep time on free days, sleep-corrected (minutes). Higher values represent a later/evening chronotype, whereas lower values represent an earlier/morning chronotype.
Time frame: Baseline
Insomnia Severity Index (ISI)
The Insomnia severity index is a 7 item measure that has each participant subjectively measure their insomnia severity. Each is rated from 0 (none/not at all) to 4 (very severe/very much). The responses are summed to produce a total score that ranges from 0 to 28; higher scores suggest great subjective insomnia severity.
Time frame: ISI completed Week 1
Demographics (DEMO)
This questionnaire better helps the investigators understand how each participant's financial, racial, social, etc. background. It ranges from general questions such as age and birthday, to socioeconomic questions such as work status and financial stability.
Time frame: Baseline
Center for Epidemiological Studies - Depression (CESD)
The Center for Epidemiologic Studies Depression Scale (CES-D) is a 20-item self-report measure of depressive symptoms experienced during the past week, with each item scored 0-3 for a total of 0-60. Commonly used cutoffs are \<16 = no significant depressive symptomatology, 16-26 = mild/moderate symptoms, and ≥27 = severe symptoms, although the CES-D is a screening measure rather than a diagnostic instrument. Higher scores indicate greater depressive symptom burden.
Time frame: CESD completed Week 1
RU Sated
Sleep is a key aspect in an individual's everyday life. This questionnaire measures overall sleep quality in six different categories---Regularity, Sleep quality, alertness, timing, efficiency, and duration. This helps investigators understand a person's sleep efficacy.
Time frame: RU Sated completed Week 1
Physical Health Questionnaire (PHQ-15)
The PHQ-15 (Patient Health Questionnaire-15) is a 15-item self-report measure of somatic symptom burden, with each symptom scored 0 (not bothered), 1 (bothered a little), or 2 (bothered a lot), producing a total score of 0-30. Commonly used severity categories are 0-4 = minimal, 5-9 = low, 10-14 = medium, and 15-30 = high somatic symptom severity.
Time frame: Baseline
Difficulties in Emotion Regulation Scale (DERS)
The Difficulties in Emotion Regulation Scale (DERS) is a 36-item self-report measure assessing difficulties with emotion regulation across six domains, with items typically rated 1 (almost never) to 5 (almost always), yielding a total score of 36-180. Higher scores indicate greater emotion-regulation difficulties, and there are no universally accepted clinical cutoff scores; scores are generally interpreted relative to normative samples or as continuous measures of emotion-regulation difficulty.
Time frame: Baseline
Dysfunctional Beliefs and Attitudes About Sleep (DBAAS)
The Dysfunctional Beliefs and Attitudes about Sleep Scale (DBAS) assesses maladaptive beliefs and expectations about sleep; the commonly used DBAS-16 contains 16 items rated on a 0-10 scale, producing a mean score from 0-10. Higher scores indicate stronger dysfunctional sleep beliefs.
Time frame: Week 1
Pain Interference and Intensity (PI-I)
This questionnaire seeks to understand how pain has an influence/impacts an individual's everyday life and activities, sleep, and mood in general. Pain intensity and interference in everyday life was assessed using a 0-5 numeric rating scale, where 0 indicates no pain and 5 indicates the worst pain imaginable. Participants rated their pain intensity and interference, with higher scores indicating greater pain severity.
Time frame: Week 2
Sorge 24 Hour Food Record
Dietary intake will be assessed using Sorge 24-hour Food Records. These records will be analyzed with the Nutrition Data System for Research (NDSR), a computer-based dietary assessment software developed by the Nutrition Coordinating Center at the University of Minnesota. Trained interviewers document all foods, beverages, and, when applicable, dietary supplements consumed during the preceding 24 hours. Information regarding food type, portion size, ingredients, preparation methods, and consumption occasions will be collected to improve the completeness and accuracy of dietary reporting. The reported dietary intake will be entered into NDSR and the resulting data may include total energy intake, macronutrients, micronutrients, and other dietary components. NDSR access is proprietary and requires a subscription. We did not have the funds to access NDSR and thus we do not have resulting data to present. The numbers below represent completed 24 hour food records for each group.
Time frame: Food record completed once during Week 2
Sorge Dietary Habits
This questionnaire asks about a person's general diet and intake.
Time frame: Sorge dietary habits completed once at Week 2
Drug Abuse Screening Test (DAST10)
The DAST-10 (Drug Abuse Screening Test-10) is a 10-item self-report screening measure of drug-related problems, with each yes/no item scored 0 or 1, producing a total score of 0-10. Common interpretation is 0 = no problems, 1-2 = low level, 3-5 = moderate, 6-8 = substantial, and 9-10 = severe drug-related problems; it is a screening tool rather than a diagnostic measure.
Time frame: Week 2
State Trait Anxiety Inventory
The State-Trait Anxiety Inventory-Trait (STAI-T) is a 20-item self-report measure of relatively stable, enduring anxiety proneness, with each item rated 1-4, producing a total score of 20-80. Higher scores indicate greater trait anxiety, but there are no universally accepted clinical severity cutoffs; scores are generally interpreted relative to normative populations, with higher scores reflecting greater anxiety tendency.
Time frame: Week 2
Penn State Cigarette Dependence Index - Cigarettes
The Penn State Cigarette Dependence Index (PSCDI) is a brief self-report measure of cigarette dependence, assessing factors such as smoking frequency, time to first cigarette, and difficulty refraining from smoking. The commonly used 9-item version produces a score of 0-9, with higher scores indicating greater nicotine dependence; there are no universally accepted clinical severity cutoffs, so scores are typically interpreted continuously or using study-specific thresholds.
Time frame: Week 2
Penn State Cigarette Dependence Index - Ecigarettes
The Penn State Electronic Cigarette Dependence Index (Penn State ECigarette Dependence Index; PS-ECDI) is a brief self-report measure of e-cigarette/vaping dependence, assessing features such as frequency of use, time to first use, and difficulty refraining. The 10-item version is scored from 0-20, with higher scores indicating greater e-cigarette dependence; commonly used categories are 0-3 = no dependence, 4-8 = low, 9-12 = moderate, 13-16 = high, and 17-20 = very high dependence.
Time frame: Week 2
Alcohol Use Disorders Identification Test - C (AUDIT)
The AUDIT-C (Alcohol Use Disorders Identification Test-Consumption) is a 3-item screening measure of alcohol consumption, with each item scored 0-4, producing a total score of 0-12. Higher scores indicate greater alcohol consumption and likelihood of hazardous drinking.
Time frame: Week 2
Alcohol Smoking and Substance Involvement Screening Test (ASSIST)
This questionnaire detects and measures substance abuse, alcohol, and smoking as well as related problems. It aims to detect the risky behavior related to each.
Time frame: Baseline up to 1 week
Anger PROMIS
The 22-item PROMIS Anger scale is a self-report measure of anger and irritability, with each item typically rated from 1 (never) to 5 (always), yielding a raw score of 22-110. Higher raw scores indicate greater anger, but raw scores are not usually interpreted with fixed clinical severity cutoffs.
Time frame: Week 2
Perceived Stress Scale (PSS)
The Perceived Stress Scale (PSS) is a 10-item self-report measure assessing how unpredictable, uncontrollable, and overwhelming respondents have found their lives during the past month. Each item is scored 0-4, producing a total raw score of 0-40; higher scores indicate greater perceived stress, but there are no universally accepted clinical severity cutoffs, so scores are generally interpreted continuously.
Time frame: Week 2
Pain Catastrophizing Scale (PCS)
The Pain Catastrophizing Scale (PCS) is a 13-item self-report measure assessing three aspects of pain catastrophizing: rumination, magnification, and helplessness. Each item is scored 0-4, producing a total raw score of 0-52; higher scores indicate greater pain catastrophizing, with ≥30 commonly used as a clinically relevant level of catastrophizing.
Time frame: Week 2
HIV Stigma Mechanisms
the HIV Stigma Mechanisms Scale (HIV-SMS) assesses three distinct dimensions of HIV-related stigma: enacted (promulgated) stigma, internalized stigma, and anticipated stigma. The original 24-item instrument uses separate five-point response scales for each dimension. Scoring and interpretation * Enacted stigma (9 items): Participants report how frequently they have experienced stigmatizing treatment because of their HIV status, using a five-point scale from 1 (never) to 5 (very often). * Internalized stigma (6 items): Participants rate their agreement with statements reflecting negative feelings or beliefs about themselves because of their HIV status, using a five-point scale from 1 (strongly disagree) to 5 (strongly agree). * Anticipated stigma (9 items): Participants rate how likely they believe others are to treat them in stigmatizing ways because of their HIV status, using a five-point scale from 1 (very unlikely) to 5 (very likely).
Time frame: Week 2
Heightened Vigilance Scale (HVS)
The Heightened Vigilance Scale is a 6-item self-report measure assessing the extent to which individuals feel they must remain alert and cautious because of the possibility of experiencing unfair treatment or discrimination. Each item is typically rated on a 1-6 scale, producing a total score of 6-36, with higher scores indicating greater perceived vigilance.
Time frame: Week 2
Experience of Discrimination (EOD)
The 9-item Experiences of Discrimination (EOD) measure assesses lifetime experiences of discrimination across nine settings, including school, employment, housing, health care, and public settings. Each item is scored according to whether the participant reports experiencing discrimination in that setting. For a situation-based total score, responses are coded as 0 (no) or 1 (yes) and summed across the nine items, yielding a total score ranging from 0 to 9. Higher scores indicate experiences of discrimination across a greater number of settings and therefore represent a worse outcome.
Time frame: Week 2
Adverse Childhood Experiences (ACE)
The Adverse Childhood Experiences (ACE) Questionnaire is a 10-item retrospective self-report measure assessing exposure to potentially traumatic or stressful experiences before age 18, including abuse, neglect, and household dysfunction. Each experience is typically scored 0 (no) or 1 (yes), producing a total ACE score of 0-10, with higher scores indicating exposure to a greater number of adverse childhood experiences
Time frame: Week 2
Lee Fatigue Scale (LFS)
The Lee Fatigue Scale (LFS) is an 18-item self-report measure assessing fatigue severity and energy level, with items rated on a 0-10 scale. Scores are typically averaged across items to produce a 0-10 overall fatigue score, with higher scores indicating greater fatigue
Time frame: Week 3
This study was conducted during the height of the COVID19 pandemic. Recruitment and retention were significantly and negatively affected. The longitudinal time-course was reduced from 8 consecutive weeks of observation down to 3 weeks. We were only able to recruit 171 of an anticipated 200 participants. Week 1: 171 total participants Week 2: 136 total participants Week 3: 35 participants (insomnia only)
| Milestone | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Started | 53 | 21 | 43 | 54 |
| Week 1 | 53 | 21 | 43 | 54 |
| Week 2 | 46 | 37 | 14 | 39 |
| Week 3 | 14 | 0 | 21 | 0 |
| Completed | 53 | 21 | 43 | 54 |
| Not completed | 0 | 0 | 0 | 0 |
TNF-a, IL-6, IL-12, IL-18, C-reactive protein, sCD14/163, D-dimer and IFN-gamma assays will be performed on the blood to identify levels of pro-inflammatory markers.
| pg/mL (picograms per milliliter) | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Tumor Necrosis Factor - Alpha (TNF-alpha) | 2.00 ± 0.801 | 1.996 ± 0.549 | 1.689 ± 0.656 | 1.563 ± 0.672 |
| Interleukin-6 (IL-6) | 1.314 ± 1.009 | 2.234 ± 2.376 | 1.482 ± 0.906 | 1.077 ± 0.811 |
| Interleukin-12 (IL-12) | 0.212 ± 0.122 | 0.279 ± 0.137 | 0.269 ± 0.219 | 0.412 ± 1.019 |
| Interleukin - 8 (IL-8) | 9.603 ± 6.407 | 10.919 ± 5.420 | 5.949 ± 3.328 | 7.115 ± 6.817 |
| C-reactive protein (CRP) | 4953.320 ± 6362.096 | 4759.150 ± 5071.101 | 5245.094 ± 5503.599 | 4233.468 ± 7156.568 |
| sCD14 | 1.457 ± 0.301 | 1.585 ± 0.361 | 1.427 ± 0.248 | 1.325 ± 0.235 |
| D-Dimer | 294.602 ± 180.747 | 288.472 ± 129.548 | 1264.445 ± 3973.323 | 611.577 ± 1358.858 |
| IFN-gamma | 7.888 ± 10.389 | 7.675 ± 5.281 | 4.866 ± 4.356 | 7.837 ± 14.118 |
IFN-a, TGF-B, IL4, IL-10 and IL-13 assays will be performed on the blood to identify levels of anti-inflammatory markers.
| pg/mL (picograms per milliliter) | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Interleukin-10 (IL-10) | 0.341 ± 0.333 | 0.372 ± 0.237 | 0.267 ± 0,117 | 0.317 ± 0.303 |
| Interleukin-13 (IL-13) | 0.608 ± 0.056 | 0.703 ± 0.025 | 1.058 ± 0.506 | 1.016 ± 0.833 |
| Transforming Growth Factor - Beta 1 (TGF-B1) | 119.192 ± 31.347 | 104.864 ± 27.557 | 133.785 ± 37.426 | 137.187 ± 32.185 |
Mitochondrial DNA damage, Damage associated molecular patterns (DAMPS) and Cortisol assays will be performed on the blood to identify levels of oxidative stress markers.
| micrograms per deciliter (µg/dL) | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Cortisol | 9.644 ± 4.556 | 11.237 ± 4.559 | 10.246 ± 3.796 | 10.829 ± 4.092 |
| Mitochondrial DAMPS - ND1 | 2.260 ± 3.811 | 1.815 ± 1.986 | 1.335 ± 1.311 | 1.889 ± 1.387 |
| Mitochondrial DAMPS - ND6 | 2.303 ± 5.740 | 1.269 ± 0.725 | 1.090 ± 0.857 | 1.311 ± 0.913 |
Pain threshold refers to the intensity at which a stimulus is first perceived as painful. Heat stimuli will be delivered using a computer-controlled thermal stimulation system with a 30 millimeter X 30 millimeter probe. From a baseline of 32 degrees Celsius, the probe temperature will increase at a rate of .5 degrees Celsius/second until the participant responds by pressing a button on a handheld device. For heat pain threshold, participants will be instructed to press the button when the sensation "first becomes painful"
| Degrees Celsius | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Pain Threshold | 43.39 ± 3.60 | 42.18 ± 4.01 | 44.12 ± 3.21 | 43.15 ± 4.09 |
Pain tolerance refers to the maximum amount of pain produced by a stimulus that a person is able/willing to tolerate. Heat stimuli will again be delivered using the computer-controlled thermal stimulation system. From a baseline of 32 degrees Celsius, the probe temperature will increase at a rate of .5 degrees Celsius/second until the participant responds by pressing a button on a handheld device. For heat pain tolerance, participants will be instructed to press the button when they are "no longer willing to tolerate" the painful sensation.
| Degrees Celsius | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Pain Tolerance | 47.26 ± 2.42 | 46.51 ± 2.18 | 47.28 ± 2.31 | 47.19 ± 2.92 |
Mechanical temporal summation was assessed using a nylon Von Frey Filament (Stoelting Co., 6.65 g), which is calibrated to bend at 300 g of pressure. The filament was applied to the back of the non-dominant hand for approximately 1 second until the monofilament bent slightly. Participants were instructed to rate their pain level using the 0-100 Numeric Rating Scale (higher numbers represent greater pain). The filament was then applied to the skin for a series of 10 consecutive applications. Participants were instructed to rate the highest level of pain they experienced during the trial. This process was repeated for two trials (2 single trials, 2 series of 10). For each trial, a difference score was calculated between the series of 10 applications and the single presentation, which represented mechanical TS. The difference score was averaged across the two trials.
| Units on a scale | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Punctate Stimuli | 20.60 ± 3.47 | 26.28 ± 5.70 | 14.53 ± 3.47 | 15.43 ± 3.15 |
Temporal summation of pain refers to a form of endogenous pain facilitation characterized by the perception of increased pain despite constant or even reduced peripheral afferent input. Temporal summation is presumed to be the psychophysical manifestation of wind-up. Wind-up is a phenomenon where repetitive stimulation of C primary afferents at rates greater than 0.3 Hertz produces a slowly increasing response of second-order neurons in the spinal cord. A series of 5 heat pulses will be repeated every two seconds starting at a baseline temperature of 40 and participants will be asked to rate how painful each peak of the pulse feels to them using a pain rating of 0-100 numeric rating scale. Pain intensity was assessed using a 0-100 numeric rating scale, where 0 indicates no pain and 100 indicates the worst pain imaginable. Participants rated their pain intensity, with higher scores indicating greater pain severity. Temperatures included 44, 46, and 48 degrees in Celsius.
| units on a scale | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Temporal summation at 44 degrees Celsius | 33.99 ± 28.82 | 29.33 ± 22.55 | 29.69 ± 22.39 | 33.48 ± 23.86 |
| Temporal summation at 46 degrees Celsius | 47.72 ± 32.77 | 42.95 ± 29.06 | 42.34 ± 27.06 | 46.71 ± 27.59 |
| Temporal summation at 48 degrees Celsius | 60.45 ± 31.22 | 56.86 ± 27.26 | 51.31 ± 31.58 | 55.05 ± 28.67 |
A cold-water bath (conditioning stimulus) was set to 10°C prior to the visit. Participants placed their non-dominant hand in the water bath up to their wrist for a maximum of 60 seconds. Immediately after withdrawal of the hand from the cold water, pressure was then applied to the dominant forearm or trapezius muscle using an algometer (testing stimulus). Participants were instructed to press a button when they first felt pain, resulting in termination of the stimuli. This procedure was repeated for a total of 4 trials (2 on each body site) and body site order was randomized (i.e., Forearm, Trapezius, Forearm, Trapezius, Forearm). An average pressure pain threshold score (kiloPascals - kPa of pressure) was generated across the two trials at each site after water immersion. Conditioned pain modulation was calculated as the difference score between baseline pressure pain threshold (kPa) and the average pressure pain threshold after water immersion at each body site
| kiloPascals of Pressure | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Conditioned pain modulation tested at the forearm | -3.40 ± 17.12 | 51.64 ± 28.09 | 5.54 ± 17.09 | 13.41 ± 15.53 |
| Conditioned pain modulation tested at the trapezius | 27.27 ± 15.98 | 30.05 ± 26.21 | 21.78 ± 15.95 | 37.16 ± 14.49 |
A light weight and compact watch-like device used for objective measurement of sleep. The device will be worn for 7 consecutive days/nights and will track physical activity, falling asleep and waking events, and includes an integrated light sensor for recording photopic light.
| Minutes | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| actigraphic wake after sleep onset (WASO) | 63.20 ± 4.35 | 62.98 ± 7.07 | 51.51 ± 4.39 | 42.28 ± 4.18 |
| actigraphic sleep onset latency (SOL) | 40.59 ± 4.39 | 17.17 ± 7.14 | 29.89 ± 4.43 | 23.46 ± 4.22 |
A sleep diary including daily questions will be filled out every day for seven days including questions about a participants nightly sleep experiences.
| Average minutes of nightly sleep | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Weekly Sleep Diaries | 372.285 ± 92.831 | 441.551 ± 76.698 | 401.730 ± 78.200 | 441.286 ± 72.781 |
A caffeine dairy including different types of caffeine generally available for the participants to record their daily caffeine consumption of for seven days.
| Average number of days per week | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Weekly Caffeine Diaries | 4.900 ± 2.511 | 5.917 ± 2.314 | 3.680 ± 2.357 | 5.022 ± 2.580 |
The Short Physical Performance Battery consists of 3 individual sub-tests - standing balance (participants are asked to stand in 3 easy stances for 10 seconds), 4-meter gait speed (participants are asked to walk a steady pace in a straight line for 4-meters) and 5-repetition sit-to-stand (participants are asked to stand up and sit back down in a stable chair up to 5 times). All 3 are simple and quick to perform in the outpatient setting and require only limited equipment. The total short physical performance battery score ranges from 0-12, with higher scores indicating better physical performance.
| Scores on a scale | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Short Physical Performance Battery | 9.29 ± 1.204 | — | 10.33 ± 1.238 | — |
The Timed Up and Go test (TUG) is a commonly used screening tool to assist clinicians to identify patients at risk of falling. Participants are asked to start in a sitting position in a chair, stand up and walk approximately 3 meters before turning to return to the chair at a steady, straight pace. The outcome will be measured with a stopwatch, then rating difficulty 0-100 (0 no difficulty and 100 being the most difficult imaginable) and pain 0-100 (0 no pain and 100 being the most pain imaginable).
| Seconds | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Timed Up and Go (TUG) Task | 10.787 ± 3.104 | — | 8.313 ± 2.514 | — |
The Munich Chronotype Questionnaire (MCTQ) estimates chronotype primarily from the midpoint of sleep on free days, called MSF (mid-sleep on free days), with MSFsc (sleep-corrected MSF) generally preferred because it adjusts for accumulated weekday sleep debt. The outcome reported in this trial is expressed in minutes - "mid-sleep time on free days, sleep-corrected (minutes). Higher values represent a later/evening chronotype, whereas lower values represent an earlier/morning chronotype.
| Minutes | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Munich Chrono Type Questionnaires (MCTQ) | 314 ± 348 | 288 ± 327 | 263 ± 284 | 237 ± 171 |
The Insomnia severity index is a 7 item measure that has each participant subjectively measure their insomnia severity. Each is rated from 0 (none/not at all) to 4 (very severe/very much). The responses are summed to produce a total score that ranges from 0 to 28; higher scores suggest great subjective insomnia severity.
| Scores on a scale | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Insomnia Severity Index (ISI) | 24.076 ± 5.177 | 15.095 ± 6.032 | 22.279 ± 4.807 | 10.907 ± 3.783 |
This questionnaire better helps the investigators understand how each participant's financial, racial, social, etc. background. It ranges from general questions such as age and birthday, to socioeconomic questions such as work status and financial stability.
| Participants | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Education attainment; high school or greater | 36 | 16 | 38 | 50 |
| Educational attainment; less than high school | 17 | 5 | 5 | 4 |
The Center for Epidemiologic Studies Depression Scale (CES-D) is a 20-item self-report measure of depressive symptoms experienced during the past week, with each item scored 0-3 for a total of 0-60. Commonly used cutoffs are \<16 = no significant depressive symptomatology, 16-26 = mild/moderate symptoms, and ≥27 = severe symptoms, although the CES-D is a screening measure rather than a diagnostic instrument. Higher scores indicate greater depressive symptom burden.
| Scores on a scale | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Center for Epidemiological Studies - Depression (CESD) | 19.50 ± 10.899 | 10.929 ± 8.343 | 15.919 ± 9.948 | 9.979 ± 8.104 |
Sleep is a key aspect in an individual's everyday life. This questionnaire measures overall sleep quality in six different categories---Regularity, Sleep quality, alertness, timing, efficiency, and duration. This helps investigators understand a person's sleep efficacy.
| Scores on a scale | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| RU Sated | 5.509 ± 2.414 | 2.200 ± 2.858 | 5.837 ± 2.103 | 9.241 ± 2.109 |
The PHQ-15 (Patient Health Questionnaire-15) is a 15-item self-report measure of somatic symptom burden, with each symptom scored 0 (not bothered), 1 (bothered a little), or 2 (bothered a lot), producing a total score of 0-30. Commonly used severity categories are 0-4 = minimal, 5-9 = low, 10-14 = medium, and 15-30 = high somatic symptom severity.
| Scores on a scale | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Physical Health Questionnaire (PHQ-15) | 10.094 ± 4.970 | 5.571 ± 4.422 | 9.023 ± 3.712 | 3.352 ± 3.742 |
The Difficulties in Emotion Regulation Scale (DERS) is a 36-item self-report measure assessing difficulties with emotion regulation across six domains, with items typically rated 1 (almost never) to 5 (almost always), yielding a total score of 36-180. Higher scores indicate greater emotion-regulation difficulties, and there are no universally accepted clinical cutoff scores; scores are generally interpreted relative to normative samples or as continuous measures of emotion-regulation difficulty.
| Scores on a scale | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Difficulties in Emotion Regulation Scale (DERS) | 77.226 ± 21.803 | 67.333 ± 23.963 | 71.534 ± 21.225 | 63.296 ± 13.941 |
The Dysfunctional Beliefs and Attitudes about Sleep Scale (DBAS) assesses maladaptive beliefs and expectations about sleep; the commonly used DBAS-16 contains 16 items rated on a 0-10 scale, producing a mean score from 0-10. Higher scores indicate stronger dysfunctional sleep beliefs.
| Scores on a scale | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Dysfunctional Beliefs and Attitudes About Sleep (DBAAS) | 5.992 ± 2.180 | 3.857 ± 2.103 | 4.635 ± 1.577 | 2.901 ± 1.413 |
This questionnaire seeks to understand how pain has an influence/impacts an individual's everyday life and activities, sleep, and mood in general. Pain intensity and interference in everyday life was assessed using a 0-5 numeric rating scale, where 0 indicates no pain and 5 indicates the worst pain imaginable. Participants rated their pain intensity and interference, with higher scores indicating greater pain severity.
| Scores on a scale | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Pain Intensity | 2.829 ± 0.945 | 2.500 ± 1.211 | 2.171 ± 0.818 | 1.527 ± 0.687 |
| Pain Interference | 2.496 ± 1.053 | 2.267 ± 1.179 | 1.743 ± 0.899 | 1.322 ± 0.742 |
Dietary intake will be assessed using Sorge 24-hour Food Records. These records will be analyzed with the Nutrition Data System for Research (NDSR), a computer-based dietary assessment software developed by the Nutrition Coordinating Center at the University of Minnesota. Trained interviewers document all foods, beverages, and, when applicable, dietary supplements consumed during the preceding 24 hours. Information regarding food type, portion size, ingredients, preparation methods, and consumption occasions will be collected to improve the completeness and accuracy of dietary reporting. The reported dietary intake will be entered into NDSR and the resulting data may include total energy intake, macronutrients, micronutrients, and other dietary components. NDSR access is proprietary and requires a subscription. We did not have the funds to access NDSR and thus we do not have resulting data to present. The numbers below represent completed 24 hour food records for each group.
| Participants | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Sorge 24 Hour Food Record | 53 | 21 | 43 | 54 |
This questionnaire asks about a person's general diet and intake.
| Participants | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Self-reported diet quality - "Excellent" | 1 | 0 | 1 | 0 |
| Self-reported diet quality - "Very good" | 9 | 2 | 4 | 10 |
| Self-reported diet quality - "Good" | 10 | 7 | 11 | 23 |
| Self-reported diet quality - "Fair" | 15 | 3 | 16 | 12 |
| Self-reported diet quality - "Poor" | 2 | 2 | 5 | 2 |
The DAST-10 (Drug Abuse Screening Test-10) is a 10-item self-report screening measure of drug-related problems, with each yes/no item scored 0 or 1, producing a total score of 0-10. Common interpretation is 0 = no problems, 1-2 = low level, 3-5 = moderate, 6-8 = substantial, and 9-10 = severe drug-related problems; it is a screening tool rather than a diagnostic measure.
| Scores on a scale | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Drug Abuse Screening Test (DAST10) | 6.421 ± 5.155 | 6.571 ± 6.345 | 2.081 ± 2.909 | 2.234 ± 3.484 |
The State-Trait Anxiety Inventory-Trait (STAI-T) is a 20-item self-report measure of relatively stable, enduring anxiety proneness, with each item rated 1-4, producing a total score of 20-80. Higher scores indicate greater trait anxiety, but there are no universally accepted clinical severity cutoffs; scores are generally interpreted relative to normative populations, with higher scores reflecting greater anxiety tendency.
| Scores on a scale | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| State Trait Anxiety Inventory | 51.567 ± 3.190 | 53.286 ± 3.891 | 51.297 ± 3.792 | 51.979 ± 3.371 |
The Penn State Cigarette Dependence Index (PSCDI) is a brief self-report measure of cigarette dependence, assessing factors such as smoking frequency, time to first cigarette, and difficulty refraining from smoking. The commonly used 9-item version produces a score of 0-9, with higher scores indicating greater nicotine dependence; there are no universally accepted clinical severity cutoffs, so scores are typically interpreted continuously or using study-specific thresholds.
| Scores on a scale | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Penn State Cigarette Dependence Index - Cigarettes | 8.447 ± 6.425 | 5.923 ± 5.514 | 1.378 ± 3.592 | 1.021 ± 3.007 |
The Penn State Electronic Cigarette Dependence Index (Penn State ECigarette Dependence Index; PS-ECDI) is a brief self-report measure of e-cigarette/vaping dependence, assessing features such as frequency of use, time to first use, and difficulty refraining. The 10-item version is scored from 0-20, with higher scores indicating greater e-cigarette dependence; commonly used categories are 0-3 = no dependence, 4-8 = low, 9-12 = moderate, 13-16 = high, and 17-20 = very high dependence.
| Scores on a scale | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Penn State Cigarette Dependence Index - Ecigarettes | 8.500 ± 3.872 | 4.000 ± 1.414 | 10.250 ± 0.957 | 8.000 ± 0.000 |
The AUDIT-C (Alcohol Use Disorders Identification Test-Consumption) is a 3-item screening measure of alcohol consumption, with each item scored 0-4, producing a total score of 0-12. Higher scores indicate greater alcohol consumption and likelihood of hazardous drinking.
| Scores on a scale | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Alcohol Use Disorders Identification Test - C (AUDIT) | 3.184 ± 2.689 | 2.643 ± 2.619 | 2.405 ± 2.217 | 2.340 ± 2.139 |
This questionnaire detects and measures substance abuse, alcohol, and smoking as well as related problems. It aims to detect the risky behavior related to each.
| Participants | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Lifetime use of Tobacco Products: Count = % reporting "yes" | 29 | 11 | 19 | 17 |
| Lifetime use of Tobacco Products: Count = % reporting "no" | 8 | 3 | 18 | 30 |
The 22-item PROMIS Anger scale is a self-report measure of anger and irritability, with each item typically rated from 1 (never) to 5 (always), yielding a raw score of 22-110. Higher raw scores indicate greater anger, but raw scores are not usually interpreted with fixed clinical severity cutoffs.
| Scores on a scale | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Anger PROMIS | 49.816 ± 16.896 | 45.143 ± 17.105 | 41.649 ± 13.992 | 38.167 ± 11.237 |
The Perceived Stress Scale (PSS) is a 10-item self-report measure assessing how unpredictable, uncontrollable, and overwhelming respondents have found their lives during the past month. Each item is scored 0-4, producing a total raw score of 0-40; higher scores indicate greater perceived stress, but there are no universally accepted clinical severity cutoffs, so scores are generally interpreted continuously.
| Scores on a scale | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Perceived Stress Scale (PSS) | 20.289 ± 5.737 | 18.214 ± 5.206 | 17.919 ± 6.062 | 15.354 ± 6.238 |
The Pain Catastrophizing Scale (PCS) is a 13-item self-report measure assessing three aspects of pain catastrophizing: rumination, magnification, and helplessness. Each item is scored 0-4, producing a total raw score of 0-52; higher scores indicate greater pain catastrophizing, with ≥30 commonly used as a clinically relevant level of catastrophizing.
| Scores on a scale | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Pain Catastrophizing Scale (PCS) | 17.868 ± 13.915 | 12.786 ± 13.016 | 8.162 ± 7.998 | 6.208 ± 7.765 |
the HIV Stigma Mechanisms Scale (HIV-SMS) assesses three distinct dimensions of HIV-related stigma: enacted (promulgated) stigma, internalized stigma, and anticipated stigma. The original 24-item instrument uses separate five-point response scales for each dimension. Scoring and interpretation * Enacted stigma (9 items): Participants report how frequently they have experienced stigmatizing treatment because of their HIV status, using a five-point scale from 1 (never) to 5 (very often). * Internalized stigma (6 items): Participants rate their agreement with statements reflecting negative feelings or beliefs about themselves because of their HIV status, using a five-point scale from 1 (strongly disagree) to 5 (strongly agree). * Anticipated stigma (9 items): Participants rate how likely they believe others are to treat them in stigmatizing ways because of their HIV status, using a five-point scale from 1 (very unlikely) to 5 (very likely).
| Scores on a scale | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Internalized HIV Stigma | 2.626 ± 1.458 | 2.271 ± 0.972 | — | — |
| Anticipated HIV Stigma | 3.495 ± 1.652 | 2.924 ± 1.236 | — | — |
| Enacted HIV Stigma | 2.757 ± 1.332 | 2.743 ± 1.287 | — | — |
The Heightened Vigilance Scale is a 6-item self-report measure assessing the extent to which individuals feel they must remain alert and cautious because of the possibility of experiencing unfair treatment or discrimination. Each item is typically rated on a 1-6 scale, producing a total score of 6-36, with higher scores indicating greater perceived vigilance.
| Scores on a scale | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Heightened Vigilance Scale (HVS) | 14.132 ± 6.200 | 11.857 ± 6.654 | 12.108 ± 5.021 | 11.583 ± 4.823 |
The 9-item Experiences of Discrimination (EOD) measure assesses lifetime experiences of discrimination across nine settings, including school, employment, housing, health care, and public settings. Each item is scored according to whether the participant reports experiencing discrimination in that setting. For a situation-based total score, responses are coded as 0 (no) or 1 (yes) and summed across the nine items, yielding a total score ranging from 0 to 9. Higher scores indicate experiences of discrimination across a greater number of settings and therefore represent a worse outcome.
| Scores on a scale | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Experience of Discrimination (EOD) | 2.632 ± 3.079 | 3.143 ± 2.381 | 2.676 ± 2.656 | 1.553 ± 2.009 |
The Adverse Childhood Experiences (ACE) Questionnaire is a 10-item retrospective self-report measure assessing exposure to potentially traumatic or stressful experiences before age 18, including abuse, neglect, and household dysfunction. Each experience is typically scored 0 (no) or 1 (yes), producing a total ACE score of 0-10, with higher scores indicating exposure to a greater number of adverse childhood experiences
| Scores on a scale | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Adverse Childhood Experiences (ACE) | 4.081 ± 2.671 | 3.357 ± 2.499 | 2.378 ± 2.190 | 1.787 ± 1.966 |
The Lee Fatigue Scale (LFS) is an 18-item self-report measure assessing fatigue severity and energy level, with items rated on a 0-10 scale. Scores are typically averaged across items to produce a 0-10 overall fatigue score, with higher scores indicating greater fatigue
| Scores on a scale | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Lee Fatigue Scale (LFS) | 4.956 ± 1.869 | — | 4.630 ± 1.215 | — |
A light weight and compact watch-like device used for objective measurement of sleep. The device will be worn for 7 consecutive days/nights and will track physical activity, falling asleep and waking events, and includes an integrated light sensor for recording photopic light. The primary actigraphic sleep outcome presented here is sleep efficiency. Sleep efficiency will be assessed using wrist-worn actigraphy and calculated as the percentage of time spent asleep relative to the total time spent in bed during the designated sleep period. Sleep efficiency is derived by dividing total sleep time by time in bed and multiplying by 100. The mean scores presented here are percentages. Higher percentages indicate greater sleep efficiency.
| Percentage | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- |
|---|---|---|---|---|
| Actigraph Sleep Measurement | 74.25 ± 1.82 | 81.32 ± 2.97 | 78.40 ± 1.84 | 79.97 ± 1.75 |
Collected over From enrollment until end of the follow-up, to to 3 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HIV+/Insomnia+ | 0/53 (0%) | 0/53 (0%) | 0/53 (0%) |
| HIV+/Insomnia- | 0/21 (0%) | 0/21 (0%) | 0/21 (0%) |
| HIV-/Insomnia+ | 0/43 (0%) | 0/43 (0%) | 0/43 (0%) |
| HIV-/Insomnia- | 0/54 (0%) | 0/54 (0%) | 0/54 (0%) |
| Age, Continuous(Years) | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- | Total |
|---|---|---|---|---|---|
| Mean | 49.94 ± 10.157 | 52.62 ± 12.164 | 41.95 ± 13.24 | 41.02 ± 12.921 | 46.38 ± 12.121 |
| Sex: Female, Male(Participants) | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- | Total |
|---|---|---|---|---|---|
| Female | 25 | 4 | 30 | 32 | 91 |
| Male | 28 | 17 | 13 | 22 | 80 |
| Race (NIH/OMB)(Participants) | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 1 |
| Asian | 0 | 0 | 3 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 48 | 17 | 24 | 30 | 119 |
| White | 4 | 3 | 16 | 20 | 43 |
| More than one race | 1 | 0 | 0 | 2 | 3 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 0 | 4 | 6 |
| Not Hispanic or Latino | 52 | 20 | 43 | 49 | 164 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 1 |
| Chronic Pain Status(Participants) | HIV+/Insomnia+ | HIV+/Insomnia- | HIV-/Insomnia+ | HIV-/Insomnia- | Total |
|---|---|---|---|---|---|
| Count of participants | 32 | 9 | 21 | 8 | 70 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jan 2020 to primary completion in Jul 2025, 66 months.
Results were first posted in Nov 2026, 1 year 3 months after primary completion.
Of 127 non-industry observational studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 42. This study's 66 months is above that.
Counting every sponsor, half of 138 studies reached it within 18 months; a quarter within 4 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sleep Initiation and Maintenance Disorders →
University of Alabama at Birmingham →